Is CVKD or CYTK more undervalued in 2026?

CirclFi compares Cadrenal Therapeutics, Inc. (CVKD) and Cytokinetics, Incorporated (CYTK) using 13 institutional-grade valuation models. CVKD has a Quality of Company score of 4.7/10 while CYTK scores 5.9/10.

Which is a better buy — CVKD or CYTK?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CVKD and CYTK valuations compare?

CVKD at $4.96 and CYTK at $76.76 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CVKD vs CYTK Valuation Comparison 2026 — Intrinsic Value Analysis

CVKD

Pharmaceutical Preparations

Cadrenal Therapeutics, Inc.

Quality

4.7

out of 10

Value Trap

—

Price

$4.96

Last close

Models

7/13

Active

CYTK

Pharmaceutical Preparations

Cytokinetics, Incorporated

Quality

5.9

out of 10

Value Trap

LOW

Price

$76.76

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	CVKD Fair Value	CVKD Upside	CYTK Fair Value	CYTK Upside
Bayesian DCF	Intrinsic	$1.43	-71.2%	$24.81	-67.7%
Earnings Power Value	Intrinsic	—	—	$21.45	-67.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.16	-76.7%	—	—
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CVKD vs CYTK — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CVKD vs CYTK — Which Stock Is More Undervalued?

CYTK scores higher with a 5.9/10 quality rating vs CVKD's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cadrenal Therapeutics, Inc. (CVKD) and Cytokinetics, Incorporated (CYTK) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CVKD currently trades at $4.96 with a QOC of 4.7/10, while CYTK trades at $76.76 with a QOC of 5.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).